Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Whitney Griffith

Nurse Practitioner Fort Myers, FL Nurse Practitioner

NPI 1578911616 CMS profile 11077248

4371 Veronica S Shoemaker Blvd, Fort Myers, FL 33916

Open in the dashboard

General payments

$10,107

505 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Whitney Griffith of Fort Myers, FL is reported in the CMS Open Payments database as having received $10,107 across 505 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,128 91
2024 General $2,728 127
2023 General $1,690 83
2022 General $1,932 107
2021 General $1,628 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Whitney Griffith
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Whitney Griffith were reported at $2,128. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Whitney Griffith Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,628 $135 $40–$426 $132
2022 $1,932 $152 $48–$470 $149
2023 $1,690 $166 $54–$529 $160
2024 $2,728 $173 $55–$556 $164
2025 $2,128 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $842 43 payments
  2. AstraZeneca Pharmaceuticals LP $737 35 payments
  3. Novartis Pharmaceuticals Corporation $681 39 payments
  4. Merck Sharp & Dohme Corporation $577 30 payments
  5. Celgene Corporation $494 20 payments
  6. Eisai Inc. $434 22 payments
  7. Daiichi Sankyo Inc. $419 21 payments
  8. Pfizer Inc. $354 19 payments
  9. Astellas Pharma US Inc $328 17 payments
  10. Seattle Genetics, Inc. $326 18 payments
  11. Other $4,915 241 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,029 504 payments
  2. Education $78 1 payment
Products named General payments · program years 2021–2025
  1. KEYTRUDA $544 28 payments
  2. Lenvima $434 22 payments
  3. ENHERTU Oncology $419 21 payments
  4. REBLOZYL $378 14 payments
  5. IMBRUVICA $354 17 payments
  6. DARZALEX $348 16 payments
  7. ZEPZELCA $302 9 payments
  8. KISQALI $289 16 payments
  9. TUKYSA $287 14 payments
  10. ENHERTU Oncology $269 13 payments
  11. Other $8,526 450 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

307

Median for Nurse Practitioner: 389

Drug cost

$20,506

Median for Nurse Practitioner: $21,885

Branded share of claims

11.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 22 $13,988
Exemestane Generic 13 $1,749
Letrozole Generic 53 $1,511
Anastrozole Generic 74 $1,298
Prochlorperazine Maleate Generic 28 $412
Famotidine Generic 32 $396
Tamoxifen Citrate Generic 24 $385
Ondansetron Odt Ondansetron Brand 13 $379
Omeprazole Generic 23 $215
Gabapentin Generic 12 $119

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 58 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REBLOZYL
  • Celgene Corporation $231
$231 — —
ENHERTU
  • AstraZeneca Pharmaceuticals LP $155
  • Daiichi Sankyo Inc. $59
$215 — —
ZEPZELCA
  • JAZZ PHARMACEUTICALS INC. $176
$176 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $143
$143 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 58 with Patron

Records

505 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record